Activity Summary:
In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:

Drs. Smith and Pellock will provide an expert analysis of the identification of Lennox-Gastaut syndrome in adults, optimal treatment options, and transition of care. The transition of pediatric patients to adults remains a challenge for providers and requires a global multidisciplinary approach.

Activity Summary:
Dr. Smith and Dr. DeToledo provide an expert review of refractory epilepsy, including proper diagnosis, imaging, seizure types, and treatment options including AEDs, surgery, VNS, and dietary considerations.